SCHEMBL1669002

SCHEMBL1669002

CS(=O)(=O)N1CCC(c2cc(F)c(OC3CN(Cc4nc(C5CC5)no4)C3)c(F)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
LMNA P02545 3/20 0.41
KMT2A Q03164 2/20 0.41
GPR119 Q8TDV5 2/20 0.38
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
POLB P06746 2/20 0.36
NPY5R Q15761 1/20 0.34
TRPA1 O75762 4/20 0.34
DPP4 P27487 1/20 0.33
PREP P48147 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
SMYD3 Q9H7B4 1/20 0.33
RORC P51449 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1668891 0.88 GPR119 (0.48) HTTLMNAKMT2AGPR119GAA
SCHEMBL1669001 0.88 GPR119 (0.41) HTTLMNAKMT2AGPR119POLB
SCHEMBL1668975 0.88 GPR119 (0.44) HTTLMNAKMT2AGPR119POLB
SCHEMBL1669280 0.87 GPR119 (0.42) HTTLMNAKMT2AGPR119POLB
SCHEMBL12198393 0.85 LMNA (0.44) LMNAKMT2AMEN1GAAPOLB
SCHEMBL1668511 0.81 GPR119 (0.45) HTTLMNAKMT2AGPR119MEN1
SCHEMBL1668403 0.81 GPR119 (0.44) LMNAKMT2AGPR119MEN1RORC
SCHEMBL1670798 0.81 GPR119 (0.52) LMNAKMT2AGPR119MEN1RORC
SCHEMBL1668525 0.81 GPR119 (0.52) HTTLMNAKMT2AGPR119MEN1
SCHEMBL1669106 0.81 CNR2 (0.35) HTTLMNAKMT2AGPR119NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 HTT 1158/4885LMNA 3232/4885KMT2A 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.